Answers are grounded in this paper and cite their sources.
Bacterial sepsis following platelet transfusion is a continuing threat. FDA issued a Final Guidance in September 2019 (updated December 2020) in which a rapid test may be used to mitigate this risk. The PGD prime Test (Verax Biomedical, Marlborough, MA, USA) is a day of transfusion, rapid, lateral-flow, qualitative immunoassay for the detection of aerobic and anaerobic Gram-positive and Gram-negative bacteria. The test may be used in the US as an FDA designated “safety measure” to extend storage of leukocyte-reduced apheresis platelets (LRAP) in plasma from 5 to 7 days in bags cleared or approved for this purpose. The PGD prime Test is a significant update to previous generations of the test. Sensitivity, specificity, training, and operational ease-of-use have all been improved. The test detects a broad range of pathogenic bacteria at concentrations below those that have been shown to cause septic transfusion reactions. Numerous publications have documented the interdiction by the test of pathogenic bacteria in platelets. This real-world experience documents the effectiveness of the test in preventing transfusion of bacterially contaminated components that have been presumed safe by negative primary culture. Use of the test to extend storage from 5 to 7 days has been demonstrated to significantly reduce outdating and save users more than the test costs to use. The specificity of the PGD prime Test was established in a validation study of 3,800 platelet components of all US platelet types except pathogen-reduced. No false-positives were detected. Specificity is 100% [lower 1-sided 95% confidence limit (LCL) 99.9%]. PGD prime is a sensitive, specific, easy to use, day of transfusion test that has been extensively validated in laboratory testing and clinical use. PGD testing has effectively interdicted the transfusion of many bacterially contaminated platelets. More than 1.4 million PGD devices have been shipped to users without a single reported fatal septic reaction resulting from the transfusion of a PGD-negative platelet. The test is specifically cleared as a “safety measure” to extend the outdate of LRAP in plasma to 7 days. As a result of reduced outdating, extending platelet dating to 7 days can save more money than the test costs while significantly enhancing platelet transfusion safety.
No takes yet. Share an insight, caveat, or question.
Mintz et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: